TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

54.32 +0.03 (+0.06%)

Delayed Quote Updated: 10:08 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Why JAKKS Pacific Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 10, 2023

Gainers Barnes & Noble Education, Inc. (NYSE: BNED) jumped 39% to $2.39 after the company posted better-than-expected quarterly sales.

Via Benzinga

Where TG Therapeutics Stands With Analysts ↗

March 01, 2023

Via Benzinga

Top 5 Health Care Stocks That May Collapse In February ↗

February 13, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Here's How Much $100 Invested In TG Therapeutics 10 Years Ago Would Be Worth Today ↗

February 07, 2023

Via Benzinga

The Latest Analyst Ratings for TG Therapeutics ↗

January 24, 2023

Via Benzinga

Here's How Much $1000 Invested In TG Therapeutics 10 Years Ago Would Be Worth Today ↗

January 19, 2023

Via Benzinga

'A Class Action Lawsuit Against TG Therapeutics Has Been Dismissed' ↗

January 13, 2023

https://www.docdroid.com/05I9eLb/tg-therapeutics-class-action-dismissal-pdf https://twitter.com/TradeHawk/status/1613997810348879874

Via Benzinga

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

Why TG Therapeutics Stock Was a Solid Winner This Week ↗

December 30, 2022

The company scored a giant victory on the regulatory front.

Via The Motley Fool

Analyst Ratings for TG Therapeutics ↗

December 30, 2022

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know ↗

December 29, 2022

Via Benzinga

B of A Securities Maintains Underperform Rating for TG Therapeutics: Here's What You Need To Know ↗

December 29, 2022

Via Benzinga

Cramer Likens This Stock To 'A Fine Merlot': It's Down 1% In 2023, So 'I Would Buy All You Can Right Here' ↗

February 08, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Parker-Hannifin Corp (NYSE: PH) is "just the kind of industrial I’ve been recommending."

Via Benzinga

TG Therapeutics Stock 300% Rally Has Legs Yet

February 08, 2023

There's further upside in the region of 30% yet to be realized, which should be more than enough to get even the more risk averse investor interested.

Via MarketBeat

EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank? ↗

January 03, 2023

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

TG Therapeutics Earnings Perspective: Return On Capital Employed ↗

December 20, 2022

Via Benzinga

Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket ↗

January 03, 2023

Gainers

Via Benzinga

Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday ↗

December 30, 2022

Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.

Via Benzinga

Shaw Communications, Enovix And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 30, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets ↗

December 29, 2022

Wednesday, the FDA approved TG Therapeutics Inc's (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS).

Via Benzinga

Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗

December 29, 2022

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.

Via Benzinga

What's Going On With TG Therapeutics Shares ↗

December 29, 2022

TG Therapeutics Inc (NASDAQ: TGTX) shares are trading higher by 9.34% to $9.25 Thursday morning. The company on Wednesday revealed FDA approval of ublituximab. What's Happening?

Via Benzinga

Tesla To $250? Here Are 10 Other Price Target Changes For Thursday ↗

December 29, 2022

Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in...

Via Benzinga

Tesla, Hyzon Motors And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 29, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket ↗

December 29, 2022

Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the...

Via Benzinga

Pfizer Makes Progress, but This Biotech Was Wednesday's Big Winner ↗

December 28, 2022

The stock market lost ground as economic worries persist.

Via The Motley Fool

Here's Why TG Therapeutics (TGTX) Shares Are Skyrocketing ↗

December 28, 2022

TG Therapeutics Inc (NASDAQ: TGTX) shares are trading higher by 8.82% to $8.51 Wednesday afternoon following FDA approval of ublituximab. What's Happening?

Via Benzinga

Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session ↗

December 28, 2022

Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal...

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗

December 16, 2022

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.